

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/562,202
				Filing Date	
				First Named Inventor	HONMOU et al.
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	1	of	11	Attorney Docket Number	038873-0108

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
/SL/	B1	WO	03/038075	A1	Renomedix Institute Inc.	05/08/2003		
/SL/	B2	WO	02/00849	A1	Hokkaido Technology Licensing Office Co., Ltd.	01/03/2002		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
/SL/	B3	AGGARWAL, et al., "Human mesenchymal stem cells modulate allogeneic immune cell responses", Blood, Vol. 105, Number 4, pp. 1815-1822, (2005).		
	B4	AKIYAMA, et al., "Transplantation of Clonal Neural Precursor Cells Derived from Adult Human Brain Establishes Functional Peripheral Myelin in the Rat Spinal Cord", Experimental Neurology, Vol. 167, pp. 27-39 (2001).		
	B5	ARCHER, et al., "Myelination by Cryopreserved Xenografts and Allografts in the Myelin-Deficient Rat", Experimental Neurology, Vol. 125, pp. 268-277 (1994).		
	B6	AUNER, et al., "Evaluation of potential risk factors for early infectious complications after autologous peripheral blood stem cell transplantation in patients with lymphoproliferative diseases", Ann Hematol, Vol. 84, pp. 532-537 (2005).		
	B7	BANG, et al., "Autologous Mesenchymal Stem Cell Transplantation in Stroke Patients", Ann Neurol, Vol. 57, pp. 874-882 (2005).		
	B8	BARKER, et al., "Acute Stroke: Evaluation with Serial Proton MR Spectroscopic Imaging", Radiology, Vol. 192, pp. 723-732 (1994).		
	B9	BEDERSON, et al., "Evaluation of 2, 3, 5-Triphenyltetrazolium Chloride as a Stain for Detection and Quantification of Experimental Cerebral Infarction in Rats", Stroke, Vol. 17, No. 6, pp. 1304-1308 (1986).		
	B10	BENDER, et al., "Identification and Comparison of CD34-Positive Cells and Their Subpopulations From Normal Peripheral Blood and Bone Marrow Using Multicolor Flow Cytometry", Blood, Vol. 77, No. 12, pp. 2591-2596 (1991).		

Examiner Signature	/Scott Long/	Date Considered	08/06/2007
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/562,202
		Filing Date	
		First Named Inventor	HONMOU et al.
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Attorney Docket Number	038873-0108
Sheet	2	of	11

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
/SL/	B11	BERNSTEIN, <i>et al.</i> , "Suppression of Human Cytotoxic T Lymphocyte Responses by Adherent Peripheral Blood Leukocytes", Annals New York Academy of Science, Vol. 532, pp. 206-213 (1988).	
	B12	BJORNSEN, <i>et al.</i> , "Turning Brain into Blood: A Hematopoietic Fate Adopted by Adult Neural Stem Cells in Vivo", Science, Vol. 283, pp. 534-537 (1999).	
	B13	BLAKEMORE, <i>et al.</i> , "Extensive Oligodendrocyte Remyelination following Injection of Cultured Central Nervous System Cells into Demyelinating Lesions in Adult Central Nervous System", Dev. Neurosci., Vol. 10, pp. 1-11 (1988).	
	B14	WIESEL, <i>et al.</i> , "Remyelination of CNS axons by Schwann cells transplanted from the sciatic nerve", Nature, Vol. 266, p. 68-69, (1977).	
	B15	Brown, <i>et al.</i> , "Factors That Influence the Collection and Engraftment of Allogeneic Peripheral-Blood Stem Cells in Patients With Hematologic Malignancies", Journal of Clinical Oncology, Vol. 15, No. 9, pp. 3067-3074 (1997).	
	B16	CHALMERS-REDMAN, <i>et al.</i> , "IN VITRO Propagation And Inducible Differentiation of Multipotential Progenitor Cells From Human Fetal Brain", Neuroscience, Vol. 76, No. 4, pp. 1121-1128 (1997).	
	B17	CHEN, <i>et al.</i> , "Therapeutic benefit of intracerebral transplantation of bone marrow stromal cells after cerebral ischemia in rats", Journal of the Neurological Sciences, Vol. 189, pp. 49-57 (2001).	
	B18	CHOPP, <i>et al.</i> , "Spinal cord injury in rat: treatment with bone marrow stromal cell transplantation", NeuronReport, Vol. 11, No. 13, pp. 3001-3005 (2000).	
	B19	DESHARI, <i>et al.</i> , "Enhanced antitumor effect of RGD fiber-modified adenovirus for gene therapy of oral cancer", Cancer Gene Therapy, Vol. 10, pp. 75-85 (2003).	

Examiner Signature	/Scott Long/	Date Considered	08/06/2007
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/562,202
		Filing Date	
		First Named Inventor	HONMOU et al.
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	3	of	11
		Attorney Docket Number	038873-0108

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/SL/	B20	ESCOLAR, <i>et al.</i> , "Transplantation of Umbilical-Cord Blood in Babies with Infantile Krabbe's Disease", The New England Journal of Medicine, pp. 2069-81 (2005).	
	B21	FLAX, <i>et al.</i> , "Engraftable human neural stem cells respond to developmental cues, replace neurons, and express foreign genes", Nature Biotechnology, Vol. 16, pp. 1033-1039 (1988).	
	B22	FRANKLIN, <i>et al.</i> , "Schwann Cell-Like Myelination Following Transplantation of an Olfactory Bulb-Ensheathing Cell Line Into Areas of Demyelination in the Adult CNS", GLIA, Vol. 17, pp. 217-224 (1996).	
	B23	FRIEDENSTEIN, A.J., "Precursor Cells of Mechanocytes", International Review of Cytology, 1976, vol. 47, pp. 327-359.	
	B24	GAGE, <i>et al.</i> , "Survival and differentiation of adult neuronal progenitor cells transplanted to the adult brain", Proc. Natl. Acad. Sci., Vol. 92, pp. 11879-11883 (1995).	
	B25	GAVRIELI, <i>et al.</i> , "Identification of Programmed Cell Death In Situ via Specific Labeling of Nuclear DNA Fragmentation", The Journal of Cell Biology, Volume 119, No. 3, pp. 493-501 (1992).	
	B26	GOTO, <i>et al.</i> , "GABA Receptor Agonist Promotes Reformation of the Striatonigral Pathway by Transplant Derived from Fetal Striatal Primordia in the Lesioned Striatum", Experimental Neurology, Vol. 147, pp. 503-509 (1997).	
	B27	GUMPEL, <i>et al.</i> , "Transplantation of Human Embryonic Oligodendrocytes into Shiverer Brain", Annals New York Academy of Sciences, Vol. 495, pp. 70-85 (1987).	

Examiner Signature	/Scott Long/	Date Considered	08/06/2007
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Complete if Known</b>	
		Application Number	10/562,202
(use as many sheets as necessary)		Filing Date	
		First Named Inventor	HONMOU et al.
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
		Attorney Docket Number	038873-0108
Sheet	4	of	11

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
/SL/	B28	HAMANO, <i>et al.</i> , "Angiogenesis Induced by the Implantation of Self-Bone Marrow Cells: A New Material for Therapeutic Angiogenesis", Cell Transplantation, Vol. 9, pp. 439-443 (2000).	
	B29	HAYASHI, <i>et al.</i> , "Reduction of Ischemic Damage by Application of Vascular Endothelial Growth Factor in Rat Brain After Transient Ischemia", Journal of Cerebral Blood Flow and Metabolism, Vol. 18, pp. 887-895 (1998).	
	B30	HIROUCHI et al., "Current state on development of neuroprotective agents for cerebral ischemia," Folia Pharmacol. Jpn., Vol. 120, pp. 107-113 (2002).	
	B31	HONMA, <i>et al.</i> , Intravenous infusion of immortalized human mesenchymal stem cells protects against injury in a cerebral ischemia model in adult rat", Experimental Neurology, pp. 1-11 (2005).	
	B32	HONMOU, <i>et al.</i> , "Restoration of Normal Conduction Properties in Demyelinated Spinal Cord Axons in the Adult Rat by Transplantation of Exogenous Schwann Cells", The Journal of Neuroscience, Vol. 16, pp. 3199-3208 (1996).	
	B33	HUSS, <i>et al.</i> , "Evidence of Peripheral Blood-Derived, Plastic-Adherent CD34 <sup>low</sup> Hematopoietic Stem Cell Clones with Mesenchymal Stem Cell Characteristics", Stem Cells, Vol., 18, pp. 252-260 (2000).	
	B34	Iihoshi, <i>et al.</i> , "A therapeutic window for intravenous administration of autologous bone marrow after cerebral ischemia in adult rats", Brain Research, Vol. 1007, pp. 1-9 (2004).	
↓	B35	IMAIZUMI, <i>et al.</i> , "Transplanted Olfactory Ensheathing Cells Remyelinate and Enhance Axonal Conduction in the Demyelinated Dorsal Columns of the Rat Spinal Cord", The Journal of Neuroscience, Vol. 18, pp. 6176-6185 (1998).	

Examiner Signature	/Scott Long/	Date Considered	08/06/2007
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/562,202
		Filing Date	
		First Named Inventor	HONMOU et al.
		Group Art Unit	Unassigned
Examiner Name	Unassigned		
Attorney Docket Number	038873-0108		
Sheet	5	of	11

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
/SL/	B36	INOUE et al., "Comparative Analysis of Remyelinating Potential of Focal and Intravenous Administration of Autologous Bone Marrow Cells Into the Rat Demyelinated Spinal Cord," GLIA, 2003, pp. 111-118, Vol. 44.	
	B37	IWADATE et al., "Induction of Immunity in Peripheral Tissues Combined with Intracerebral Transplantation of Interleukin-2-producing Cells Eliminates Established Brain Tumors," Cancer Research, Dec. 15, 2001, pp. 8769-8774, Vol. 61.	
	B38	KANEGAE et al., "Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase," Nucleic Acids Research, 1995, pp. 3816-3821, Vol. 23, No. 19.	
	B39	KATO et al., "Transplantation of Human Olfactory Ensheathing Cells Elicits Remyelination of Demyelinated Rat Spinal Cord," GLIA, 2000, pp. 209-218, Vol. 30.	
	B40	KAWANO et al., "Ex vivo expansion of human umbilical cord hematopoietic progenitor cells using a coculture system with human telomerase catalytic subunit ( <i>hTERT</i> )—transfected human stromal cells," Blood, Jan. 15, 2003, pp. 532-540, Vol. 101, No. 2.	
	B41	KEIRSTEAD et al., "Polysialylated Neural Cell Adhesion Molecule-Positive CNS Precursors Generate Both Oligodendrocytes and Schwann Cells to Remyelinate the CNS after Transplantation," J. Neurosci., Sept. 1, 1999, pp. 7529-7536, Vol. 19, No. 17.	
	B42	KOBUNE et al., "Telomerized human multipotent mesenchymal cells can differentiate into hematopoietic and cobblestone area-supporting cells," Experimental Hematology, 2003, pp. 715-722, Vol. 31, Elsevier Inc.	
↓	B43	KOÇ et al., "Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and hurler syndrome (MPS-IH), Bone Marrow Transplantation, 2002, pp. 215-222, Vol. 30.	

Examiner Signature	/Scott Long/	Date Considered	08/06/2007
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number Filing Date First Named Inventor Group Art Unit Examiner Name Attorney Docket Number	10/562,202  HONMOU et al. Unassigned Unassigned 038873-0108
Sheet	6	of	11

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
/SL/	B44	KOÇ et al., "Rapid Hematopoietic Recovery After Coinfusion of Autologous-Blood Stem Cells and Culture-Expanded Marrow Mesenchymal Stem Cells in Advanced Breast Cancer Patients Receiving High-dose Chemotherapy," J. Clin. Oncol., 2000, pp. 307-316, Vol. 18, No. 2.	
	B45	KOPEN et al., "Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains," Proc. Natl. Acad. Sci., Sept. 1999, pp. 10711-10716, Vol. 96, USA.	
	B46	KUROZUMI et al., "BDNF Gene-Modified Mesenchymal Stem Cells Promote Functional Recovery and Reduce Infarct Size in the Rat Middle Cerebral Artery Occlusion Model," Molecular Therapy, Feb. 2004, pp. 189-197, Vol. 9, No. 2.	
	B47	LOIS et al., "Proliferating subventricular zone cells in the adult mammalian forebrain can differentiate into neurons and glia," Proc. Natl. Acad. Sci., Mar. 1993, pp. 2074-2077, Vol. 90, USA	
	B48	LONGA et al., "Reversible Middle Cerebral Artery Occlusion Without Craniectomy in Rats," Stroke, January 1989, vol. 20, no. 1, pp. 84-91.	
	B49	MAJUMDAR et al., "Phenotypic and Functional Comparison of Cultures of Marrow-Derived Mesenchymal Stem Cells (MSCs) and Stromal Cells," J. Cell. Physiol., 1998, pp. 57-66, Vol. 176.	
	B50	J. MOKRY, "Experimental Models and Behavioural Tests Used in the Study of Parkinson's Disease," Physiol. Res., 1995, pp. 143-150, Vol. 44, No. 3.	
	B51	R. MORRIS, "Spatial Localization Does Not Require the Presence of Local Cues," Learning and Motivation, 1981, pp. 239-260, Vol. 12.	

Examiner Signature	/Scott Long/	Date Considered	08/06/2007
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete If Known</b>	
		Application Number	10/562,202
		Filing Date	
		First Named Inventor	HONMOU et al.
		Group Art Unit	Unassigned
Examiner Name	Unassigned		
Attorney Docket Number	038873-0108		
Sheet	7	of	11

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>8</sup>
/SL/	B52	MORSHEAD et al., "Neural Stem Cells in the Adult Mammalian Forebrain: A Relatively Quiescent Subpopulation of Subependymal Cells," Neuron, Nov. 1994, pp. 1071-1082, Vol. 13.	
	B53	MOYER et al., "Culture, Expansion, and Transplantation of Human Fetal Neural Progenitor Cells," Transplantation Proceedings, 1997, pp. 2040-2041, Vol. 29, Elsevier.	
	B54	NAKAGAWA et al., "Persistent and Secondary Adenovirus-Mediated Hepatic Gene Expression Using Adenovirus Vector Containing CTLA4IgG," Hum. Gene Ther., Aug. 10, 1998, pp. 1739-1745, Vol. 9, No. 12, Mary Ann Liebert, Inc.	
	B55	NAKAMURA et al., "Effective Gene Transfer to Human Melanomas via Integrin-Targeted Adenoviral Vectors," Hum. Gene Ther., Mar. 20, 2002, pp. 613-626, Vol. 13.	
	B56	NAKAMURA et al., "Adoptive Immunotherapy with Murine Tumor-specific T Lymphocytes Engineered to Secrete Interleukin 2," Cancer Research, Nov. 15, 1994, pp. 5757-5760, Vol. 54, No. 22.	
	B57	NAMBA et al., "Evaluation of the Bystander Effect in Experimental Brain Tumors Bearing Herpes Simplex Virus-Thymidine Kinase Gene by Serial Magnetic Resonance Imaging," Hum. Gene Ther., Oct. 1, 1996, pp. 1847-1852, Vol. 7, No. 15, Mary Ann Liebert, Inc.	
	B58	NEUMANN-HAEFELIN et al., "Serial MRI After Transient Focal Cerebral Ischemia in Rats," Stroke, Aug. 2000, pp. 1965-1973.	
	B59	NIWA et al., "Efficient selection for high-expression transfectants with a novel eukaryotic vector," Gene, 1991, pp. 193-199, Vol. 108.	

Examiner Signature	/Scott Long/	Date Considered	08/06/2007
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete If Known</b>	
		Application Number	10/562,202
		Filing Date	
		First Named Inventor	HONMOU et al.
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	8	of	11
		Attorney Docket Number	038873-0108

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
/SL/	B60	NOMURA et al., "I.V. Infusion of Brain-Derived Neurotrophic Factor Gene-Modified Human Mesenchymal Stem Cells Protects Against Injury in a Cerebral Ischemia Model in Adult Rat," Neuroscience, 2005, pp. 161-169, Vol. 136.	
	B61	NYBERG-HOFFMAN et al., "Sensitivity and reproducibility in adenoviral infectious titer determination," Nature Medicine, July 1997, pp. 808-811, Vol. 3, No. 7.	
	B62	OHLSSON et al., "Environment Influences Functional Outcome of Cerebral Infarction in Rats," Stroke, Apr. 1995, pp. 644-649, Vol. 26, No. 4.	
	B63	PAXINOS et al., "Bregma, lambda and the interaural midpoint in stereotaxic surgery with rats of different sex, strain and weight," J. Neurosci. Methods, 1985, pp. 139-143, Vol. 13, Elsevier.	
	B64	PLUCHINO et al., "Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism," Nature, July 14, 2005, pp. 266-271, Vol. 436.	
	B65	PLUCHINO et al., "Injection of adult neurospheres induces recovery in a chronic model of multiple sclerosis," Nature, Apr. 17, 2003, pp. 688-694, Vol. 422.	
	B66	PROCKOP et al., "One strategy for cell and gene therapy: Harnessing the power of adult stem cells to repair tissues," PNAS, Sept. 30, 2003, pp. 11917-11923, Vol. 100, Suppl. 1.	
	B67	D. PROCKOP, "Marrow Stromal Cells as Stem Cells for Nonhematopoietic Tissues," Science, Apr. 4, 1997, pp. 71-74, Vol. 276.	

Examiner Signature	/Scott Long/	Date Considered	08/06/2007
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete If Known</b>	
		Application Number Filing Date First Named Inventor Group Art Unit Examiner Name Attorney Docket Number	10/562,202  HONMOU et al. Unassigned Unassigned 038873-0108
Sheet	9	of	11

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
/SL/	B68	REYNOLDS et al., "Generation of Neurons and Astrocytes from Isolated Cells of the Adult Mammalian Central Nervous System," Science, Mar. 27, 1992, pp. 1707-1710, Vol. 255.	
	B69	RHINES et al., "Local Immunotherapy with Interleukin-2 Delivered from Biodegradable Polymer Microspheres Combined with Interstitial Chemotherapy: A Novel Treatment for Experimental Malignant Glioma," Neurosurgery, Apr. 2003, pp. 872-880, Vol. 52, No. 4.	
	B70	ROCHEFORT et al., "Influence of hypoxia on the domiciliation of Mesenchymal Stem Cells after infusion into rats: possibilities of targeting pulmonary artery remodeling via cells therapies?" Respiratory Research, 2005, pp. 1-13, Vol. 6, No. 125.	
	B71	SASAKI et al., "Protection of Corticospinal Tract Neurons After Dorsal Spinal Cord Transection and Engraftment of Olfactory Ensheathing Cells," GLIA, 2006, pp. 352-359, Vol. 53.	
	B72	SASAKI et al., "Transplantation of an Acutely Isolated Bone Marrow Fraction Repairs Demyelinated Adult Rat Spinal Cord Axons," GLIA, 2001, pp. 26-34, Vol. 35.	
	B73	STABA et al., "Cord-Blood Transplants from Unrelated Donors in Patients with Hurler's Syndrome," N. Engl. J. Med., May 6, 2004, pp. 1960-1969, Vol. 350, No. 19.	
	B74	SVENDSEN et al., "Long-Term Survival of Human Central Nervous System Progenitor Cells Transplanted into a Rat Model of Parkinson's Disease," Experimental Neurology, 1997, pp. 135-146, Vol. 148, Article No. EN976634.	
	B75	TAKIGUCHI et al., "CTLA4IgG Gene Delivery Prevents Autoantibody Production and Lupus Nephritis in MRL/lpr Mice," Life Sciences, 2000, pp. 991-1001, Vol. 66, No. 11, Elsevier.	

Examiner Signature	/Scott Long/	Date Considered	08/06/2007
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/562,202
		Filing Date	
		First Named Inventor	HONMOU et al.
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	10	of	11
		Attorney Docket Number	038873-0108

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/SL/	B76	TAMURA et al., "Focal cerebral infarction in the rat: I. Operative technique and physiological monitorings for chronic model," No To Shinkei, 1986, vol. 38, no. 8, pp. 747-751.	
	B77	TILLE et al., "Mesenchymal Cells Potentiate Vascular Endothelial Growth Factor-Induced Angiogenesis in Vitro," Experimental Cell Research, 2002, pp. 179-191, Vol. 280.	
	B78	TOMA et al., "Human Mesenchymal Stem Cells Differentiate to a Cardiomyocyte Phenotype in the Adult Murine Heart," Circulation, Jan. 1/8, 2002, pp. 93-98.	
	B79	TONDREAU et al., "Mesenchymal Stem Cells Derived from CD133-Positive Cells in Mobilized Peripheral Blood and Cord Blood: Proliferation, Oct4 Expression, and Plasticity," Stem Cells, 2005, pp. 1105-1112, Vol. 23.	
	B80	TSUDA et al., "Efficient BMP2 Gene Transfer and Bone Formation of Mesenchymal Stem Cells by a Fiber-Mutant Adenoviral Vector," Mole. Therapy, Mar. 2003, pp. 354-365, Vol. 7, No. 3.	
	B81	UTZSCHNEIDER et al., "Transplantation of glial cells enhances action potential conduction of amyelinated spinal cord axons in the myelin-deficient rat," Proc. Natl. Acad. Sci., Jan. 1994, pp. 53-57, Vol. 91, USA.	
	B82	VILLARON et al., "Mesenchymal stem cells are present in peripheral blood and can engraft after allogeneic hematopoietic stem cell transplantation," Haematologica, Dec. 2004, pp. 1421-1427, Vol. 89, No. 12.	
	B83	WILLING et al., "Mobilized Peripheral Blood Cells Administered Intravenously Produce Functional Recovery in Stroke," Cell Transplant., 2003, pp. 449-454, Vol. 12, USA.	

Examiner Signature	/Scott Long/	Date Considered	08/06/2007
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number Filing Date First Named Inventor Group Art Unit Examiner Name Attorney Docket Number	10/562,202  HONMOU et al. Unassigned Unassigned 038873-0108
Sheet	11	of	11

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
/SL/	B84	YANDAVA et al., "Global' cell replacement is feasible via neural stem cell transplantation: Evidence from the dysmyelinated <i>shiverer</i> mouse brain," Proc. Natl. Acad. Sci., June 1999, pp. 7029-7034, Vol. 96, USA.	
	B85	WOODBURY et al., "Adult Rat and Human Bone Marrow Stromal Cells Differentiate Into Neurons," J. Neurosci. Res., 2000, pp. 364-370, Vol. 61.	
	B86	YAMAUCHI et al., "Pre-administration of angiopoietin-1 followed by VEGF induces functional and mature vascular formation in a rabbit ischemic model," J. Gene Med., 2003, pp. 994-1004, Vol. 5.	
	B87	ZHANG et al., "Human bone marrow stromal cell treatment improves neurological functional recovery in EAE mice," Exper. Neurology, 2005, pp. 16-26, Vol. 195, Elsevier.	
	B88	ZVAIFLER et al., "Mesenchymal precursor cells in the blood of normal individuals," Arthritis Res., 2000, pp. 477-488, Vol. 2, No. 6.	

Examiner Signature	/Scott Long/	Date Considered	08/06/2007
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

10/562202

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

APPROVED PTO 23 DEC 2005

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

Date Submitted: December 23, 2005

(use as many sheets as necessary)

Application Number	Unassigned
Filing Date	December 23, 2005
First Named Inventor	Osamu HONMOU
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	033873-0108

Sheet 1 of 2

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

## U.S. PATENT APPLICATION DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Application Document		Name of Patentee or Applicant of Cited Document	Filing Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Serial Number	Kind Code <sup>2</sup> (if known)			

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
/SL/	A1		JP 2004-544234 A		HENRY FORD HEALTH SYSTEM	12/24/2002		
/SL/	A2		WO 01/66698 A1		CRYO-CELL INT. INC.	9/13/2001		
/SL/	A3		WO 03/25167 A2		CENT TRANSLATIONAL RES IN CANCER	3/27/2003		

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
/SL/	A4	DATABASE BIOSIS ON STN, (Last Updated on Stn: 6/19/2003) abstract no. 200300283245 & S. IIHOSHI et al., "Intravenous administration of autologous bone marrow cells repairs the ischemic lesions in the rat middle cerebral artery occlusion model", Society for Neuroscience Abstract Viewer & Itinerary Planner, (2002), vol. 2002, abstract no. 237.8., <a href="http://sfn.scholarone.com">http://sfn.scholarone.com</a>	
	A5	D. LU et al., "Adult bone marrow stromal cells administered intravenously to rats after traumatic brain injury migrate to brain and improve neurological outcome", Neuroreport, 2001, vol. 12, No. 3, pp. 559-563.	
	A6	J. CHEN et al., "Therapeutic benefit of intravenous administ ratino of bone marrow stromal cells after cerebral ischemia in rats", Stroke, 2001, Vol. 32, No. 4, pp. 1005-1011.	
	A7	K. CHU et al., "Human neural stem cells can migrate, differentiate and integrate after intravenous transplantation in adult rats with transient forebrain ischemia", Neurosci. Lett., 6/5/2003, Vol. 343, No. 2, pp. 129-133.	
	A8	Y. AKIYAMA et al., "Remyelination of the spinal cord following intravenous delivery of bone marrow cells", Glia., (2002), Vol. 39, pp. 229-236.	

Examiner  
Signature

/Scott Long/

Date  
Considered

08/06/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

WASH\_1518208.1

10/562202

MODIFIED PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>IP9 PCT/PTO 23 DEC 2005</b>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	Unassigned
Date Submitted: December 23, 2005		Filing Date	December 23, 2005
(use as many sheets as necessary)		First Named Inventor	Osamu HONMOU
		Group Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	2 of 2	Attorney Docket Number	033873-0108

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
/SL/	A9	A. MAHMOOD et al., "Treatment of traumatic brain injury in female rats with intravenous administration of bone marrow stromal cells", Neurosurgery, 2002, vol. 49, no. 5, pp. 1196-1203.	
	A10	DATABASE MEDLINE ON STN, (2002), abstract no. 2002333228 & D. LU et al., "Intravenous administration of human umbilical cord blood reduces neurological deficit in the rat after traumatic brain injury", Cell Transplant. (2002), Vol. 11, No. 3, pp. 275-281.	
	A11	DATABASE BIOSIS ON STN, (2001), abstract no. 200100547979 & Y. AKIYAMA et al., "Remyelination of spinal cord axons by intravenous delivery of bone marrow cells", Society for Neuroscience Abstracts, 2001, Vol. 27. No. 2, pg. 1562.	
	A12	DATABASE BIOSIS IN STN, (2003), abstract no. 200300315449 & P. LU et al., "Transplantation of bone marrow stromal cells (MSCs) and BDNF-transducer MSCs promotes robust axonal growth after spinal cord injury", Society for Neuroscience Abstract Viewer & Itinerary Planner, 2002, Vol. 202, abstract no. 634.11 <a href="http://stn.scholarone.com">http://stn.scholarone.com</a> .	
	A13	MA KEANE-MOORE et al., "Human mesenchymal stem cells can be genetically modified to function as antigen presenting cells", Blood, (1998), Vol. 92, No. 10, suppl. 1, part 1 to 2, pg. 338A, Abstract #1388.	

Examiner Signature	/Scott Long/	Date Considered	08/06/2007
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

WASH\_1518208.1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Date Submitted: June 6, 2007

(use as many sheets as necessary)

1

of

1

**Complete if Known**

Application Number	10/562,202
Filing Date	6/25/2004
First Named Inventor	Osamu HONMOU
Art Unit	3629
Examiner Name	Unassigned
Attorney Docket Number	033873-0108

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
/SL/	C1	2003/0161818 A1	08/28/2003	Weiss et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code* Number* Kind Code <sup>5</sup> (if known)				
/SL/	C2	WO 99/01145	01/14/1999	Osiris Therapeutics, Inc.		
/SL/	C3	WO 01/005944 A1	01/25/2001	University of Southern California		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
/SL/	C4	KENNEA et al., "Perinatal applications of neural stem cells," Best Practice & Research Clinical Obstetrics and Gynaecology, 2004, 18(6), 977-994.	
/SL/	C5	TOCCI et al., "Mesenchymal stem cell: use and perspectives," The Hematology Journal, 2003, 4, 92-96.	

Examiner  
Signature

/Scott Long/

Date  
Considered

08/06/2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinda Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  Date Submitted: July 14, 2006 (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/562,202
				Filing Date	6/25/2004
				First Named Inventor	Osamu HONMOU
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	1	of	1	Attorney Docket Number	033873-0108

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
/SL/	C1	JP	2002-027983	A	Applied Cell Biotechnologies, Inc.	01/29/2002		A
/SL/	C2	JP	2002-544234	A	Henry Ford Health System	12/24/2002		A

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
/SL/	C3	The Hokkaido Shimibun, "Treatment of cerebral infarction with the patient's own bone-marrow stem cells collected in advance," Sapporo Medical University, July 7, 2003, one page (and English Translation, two pages).	
/SL/	C4	"Gene therapy for rat glioma based on mesenchymal stem cell transplantation," Cancer Science, September 25-27, 2003, Proceedings of the 62 <sup>nd</sup> Annual Meeting of the Japanese Cancer Association, five pages including cover, table of contents, p. 325 and last page of publication (and English translation of p. 325, one page).	

Examiner Signature	/Scott Long/	Date Considered	08/06/2007
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.